©Author(s) (or their employer(s)) 2026.
World J Clin Pediatr. Mar 9, 2026; 15(1): 114054
Published online Mar 9, 2026. doi: 10.5409/wjcp.v15.i1.114054
Published online Mar 9, 2026. doi: 10.5409/wjcp.v15.i1.114054
Table 3 Biomarkers characteristics
| Biomarker/panel | Clinical context | Platform (discovery validation) | Threshold (per study) | AUC (95%CI) | Sens | Spec | Notes |
| Interleukin-27 | Sepsis vs systemic inflammatory response syndrome (diagnostic) | Transcriptomics-driven discovery to serum immunoassay | ≥ 5.0 ng/mL | 0.811 (0.755-0.868) | 0.61 | 0.92 | “Rule-in” behavior; outperformed PCT; classification and regression tree with PCT improved prediction |
| HP (infants) | Prognosis (poor outcome) | TMT-LC-MS/MS to ELISA | Study-defined | 0.875 (0.700-1.000) | 0.83 | 1.00 | Opposite directionality in toddlers; age-adapted use essential |
| THBS1 (infants) | Prognosis (poor outcome) | TMT-LC-MS/MS to ELISA | 218.38 ng/mL | 0.877 (0.701-1.000) | 1.00 | 0.60 | Infant-specific signal; not significant in toddlers |
| HP + THBS1 (infants, combined) | Prognosis (poor outcome) | TMT-LC-MS/MS to ELISA | Panel score | 0.958 (0.868-1.000) | 0.917 | 1.00 | Best infant prognostic combo |
| Serum amyloid A 1 | Sepsis vs healthy (diagnostic) | Label-free LC-MS to ELISA | 35891 ng/mL (Youden) | 0.978 (0.946-1.000) | 0.889 | 1.00 | Early rising acute-phase protein; split patients/controls cleanly |
| Soluble CD25 | Sepsis vs healthy (diagnostic) | Label-free LC-MS to ELISA | 3209 pg/mL (Youden) | 0.970 (0.920-1.000) | 0.946 | 1.00 | Performed better than PCT in intensive care unit admission cohorts (cited by authors) |
| Leucine-rich alpha-2-glycoprotein 1 | Sepsis vs healthy (diagnostic) | Label-free LC-MS to ELISA | 56951.5 ng/mL (Youden) | 0.933 (0.86-1.00) | 0.867 | 0.89 | Acute-phase-responsive glycoprotein; strong single-marker ROC |
| Slow off-rate modified aptamer (capture reagent) signature (multi-protein) | Sepsis vs post- cardiopulmonary bypass infection-negative systemic inflammation (diagnostic differentiation) | SOMAscan (aptamer-based high-plex proteomic platform) 1305-plex; linear models for microarray data + Benjamini-Hochberg false-discovery-rate correction, Boruta; weighted gene co-expression network analysis | - | - | - | - | 111 differentially ex-pressed (proteins/genes) proteins (8.6% of panel); sepsis-correlated modules identified; no single-analyte ROC reported |
- Citation: Sabitova G, Makhammajanov Z, Khvan M, Tarlykov P, Sazonov V. Proteomic biomarkers for early diagnosis and prognosis in pediatric sepsis. World J Clin Pediatr 2026; 15(1): 114054
- URL: https://www.wjgnet.com/2219-2808/full/v15/i1/114054.htm
- DOI: https://dx.doi.org/10.5409/wjcp.v15.i1.114054